Primary hormone treatment in postmenopausal women with breast cancer

被引：0
作者：
Escalante S.M. [1 ]
Sanz V.P. [1 ]
Lescure A.R. [1 ]
Navarro I.B. [1 ]
Mena A.C. [1 ]
机构：
[1] Department of Medical Oncology, Hospital General Universitario de Elche, 03202 Elche, Alicante
来源：
Clinical and Translational Oncology | 2006年 / 8卷 / 5期
关键词：
Aromatase inhibitors; Hormone therapy; Neoadjuvant treatment; Postmenopausal women;
D O I：
10.1007/s12094-006-0185-7
中图分类号：
学科分类号：
摘要：
Clinical benefits of hormone therapy in patients with hormone-sensitive tumors have been clearly established. Postmenopausal women with positive hormone receptors represent the largest group of patients in whom early stage breast cancer is diagnosed. Third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are active and well tolerated in postmenopausal women with hormone-sensitive metastasic or locally advanced breast cancer as first or second line treatment. These are also valuable agents in the neoadjuvant setting in postmenopausal women, and even as single treatment in localized breast tumors in women not amenable to surgery. © FESEO 2006.
引用
收藏
页码：372 / 374
页数：2
相关论文
共 50 条
  • [31] Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
    Aktas, Bilge
    Sorkin, Mia
    Pusztai, Lajos
    Hofstatter, Erin W.
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2016, 25 (01) : 3 - 8
  • [32] Hormone therapy and breast cancer
    de Cremoux, Patricia
    BULLETIN DU CANCER, 2011, 98 (11) : 1311 - 1319
  • [33] Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?
    Dieli-Conwright, Christina M.
    Sullivan-Halley, Jane
    Patel, Alpa
    Press, Michael
    Malone, Kathleen
    Ursin, Giske
    Burkman, Ronald
    Strom, Brian
    Simon, Michael
    Weiss, Linda
    Marchbanks, Polly
    Folger, Suzanne
    Spirtas, Robert
    Deapen, Dennis
    Bernstein, Leslie
    CANCER CAUSES & CONTROL, 2011, 22 (03) : 515 - 522
  • [34] Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women?
    Christina M. Dieli-Conwright
    Jane Sullivan-Halley
    Alpa Patel
    Michael Press
    Kathleen Malone
    Giske Ursin
    Ronald Burkman
    Brian Strom
    Michael Simon
    Linda Weiss
    Polly Marchbanks
    Suzanne Folger
    Robert Spirtas
    Dennis Deapen
    Leslie Bernstein
    Cancer Causes & Control, 2011, 22 : 515 - 522
  • [35] Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer
    Pan, Kathy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 147 - 153
  • [36] Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer
    Tusquets Trias de Bes, Ignasi
    Tormo, Sonia Servitja
    Mestres, Joan Albanell
    BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (01) : 1 - 10
  • [37] Aromatase inhibitors: A new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women
    Colozza, M.
    Califano, R.
    Minenza, E.
    Dinh, P.
    Azambuja, E.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (06) : 564 - 574
  • [38] Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
    Gonnelli, Stefano
    Petrioli, Roberto
    CLINICAL INTERVENTIONS IN AGING, 2008, 3 (04): : 647 - 657
  • [39] Aromatase Inhibitors Evolution as Potential Class of Drugs in the Treatment of Postmenopausal Breast Cancer Women
    Avvaru, Stephen Paul
    Noolvi, Malleshappa N.
    Aminbhavi, Tejraj M.
    Chkraborty, Sudipta
    Dash, Ashutosh
    Shukla, Shyam S.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2018, 18 (07) : 609 - 621
  • [40] Postmenopausal hormone therapy and the risk of breast cancer: the view of an epidemiologist
    Li, CI
    MATURITAS, 2004, 49 (01) : 44 - 50
12345